Immatics Unveils Early-Stage Data Of TCR-Engineered Cell Therapy In Solid Tumors

Immatics N.V. IMTX announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine IMA203 targeting PRAME.
Examining the drug’s effect on 16 cancer patients who had already endured a median of 4 previous systemic treatments, researchers concluded that 8 of them had registered an objective response.
Three of the patients who didn’t respond were on the lowest dose, while investigators tracked encouraging dose responses at higher levels.
15 out of 16 patients (94%) achieved disease control. Tumor shrinkage was observed in 14 patients (88%).
All responses occurred above DL1; 8 out of 13 patients (62%) treated at DL20F1 and DL3 receiving up to 0.59 billion total transduced cells had objective partial responses.
Investors and analysts didn’t seem all that impressed, however.
The next level is a big step up, at 2.5 billion transduced cells, that fourth dosage will be the highest dose level.
Price Action: IMTX shares are down 11.2% at $11.16 during the market session on the last check Tuesday.